Bicara Therapeutics is a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors.
As a clinical-stage company, Bicara’s financial statements did not report any revenue for 2025. The company reported a basic and diluted Earnings Per Share (EPS) net loss of $(0.68) for the fourth quarter of 2025 and $(2.52) for the full year. The total net loss was $138.0 million for the year ended December 31, 2025.
Bicara ended 2025 with $414.8 million in cash, cash equivalents, and marketable securities. Full-year research and development expenses reached $125.1 million. Based on current plans, the company expects its capital to fund operations into the first half of 2029.
This article was generated with the assistance of AI technology and reviewed for accuracy. AlphaStreet may receive compensation from companies mentioned in this article. This content is for informational purposes only and should not be considered investment advice.